Siren Biotechnology Awarded $8M from CIRM for SRN-101
Scottsdale, AZ — June 26, 2026 · KMAK Capital
The California Institute for Regenerative Medicine has awarded portfolio company Siren Biotechnology an $8 million non-dilutive CLIN2 grant to support clinical development of SRN-101, its lead investigational AAV immuno-gene therapy for high-grade glioma brain cancers.
The award follows FDA clearance of Siren’s first IND earlier in 2026, which enabled a Phase 1/2 trial in adult patients with recurrent high-grade glioma. The CIRM funding supports the conduct of that trial and related activities.
“High-grade gliomas remain among the hardest cancers to treat, and patients cannot wait.”
SRN-101 is built on Siren’s Universal AAV Immuno-Gene Therapy platform, designed to deliver immune-modulating payloads directly within tumors. The program has received Fast Track, Orphan Drug, and Rare Pediatric Disease designations from the FDA. CIRM previously provided a $4 million TRAN1 grant at the translational stage.
Non-dilutive capital funds clinical work without touching the cap table, and CIRM returning with a second, larger award is its own signal.